Overview

Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

Status:
RECRUITING

Trial end date:
2028-12-31

Target enrollment:

Participant gender:

Summary

This study targeted patients with resectable stage II-IIIA non-small cell lung cancer with EGFR mutation

Phase:

PHASE2

Details

Lead Sponsor:

Peng Zhang